Blue Jet Healthcare Ltd

About Blue Jet Healthcare Ltd

Blue Jet Healthcare Ltd is a leading Indian manufacturer of specialty pharmaceutical ingredients, focusing on contrast media intermediates, high-intensity sweeteners, and pharmaceutical intermediates/APIs. Serving global innovator and generic pharmaceutical companies, the company excels in complex chemistry and stringent regulatory environments, establishing a strong market presence in niche therapeutic segments.

Key Financial Ratios of Blue Jet Healthcare Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Blue Jet Healthcare Ltd's P/E ratio (TTM) is 0.26, compared to the industry median of 19.41 and large cap median of 18.08.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Blue Jet Healthcare Ltd's P/B ratio is N/A, compared to the industry median of 1.98 and large cap median of 2.03.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Blue Jet Healthcare Ltd's P/S ratio is 12.55, compared to the industry median of 2.06 and large cap median of 1.64.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Blue Jet Healthcare Ltd's PEG ratio is 1.70.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Blue Jet Healthcare Ltd's EV/EBITDA ratio is 29.82.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Blue Jet Healthcare Ltd's ROE is 40%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Blue Jet Healthcare Ltd's ROA is 38.43%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Blue Jet Healthcare Ltd's ROCE is 57%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Blue Jet Healthcare Ltd's operating margin is 41.28%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Blue Jet Healthcare Ltd's net margin is 27.25%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Blue Jet Healthcare Ltd's current ratio is N/A.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Blue Jet Healthcare Ltd's debt-to-equity ratio is 0.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Blue Jet Healthcare Ltd's interest coverage ratio is 38.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Blue Jet Healthcare Ltd's DPS is ₹0.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Blue Jet Healthcare Ltd's EPS is -94.22.

(Source line: "Ratios as of 23 Oct 2026, based on last traded price of ₹359.95. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1968

• Headquarters: Mumbai, Maharashtra

• Core Offerings: Contrast Media Intermediates, High-intensity Sweeteners, Pharmaceutical Intermediates, Active Pharmaceutical Ingredients (APIs)

• Stock Listing: NSE (BLUEJET), BSE (544009)

• Promoter: Goenka Family / Blue Jet Promoter Group

History of Blue Jet Healthcare Ltd

Blue Jet Healthcare Limited was incorporated in 1968, initially establishing its presence in specialty chemicals. Over the decades, the company strategically expanded its portfolio, becoming a prominent global manufacturer of contrast media intermediates. It further diversified into high-intensity sweeteners like saccharin and acesulfame potassium, and developed capabilities in niche pharmaceutical intermediates and APIs, including controlled substances. In 2023, Blue Jet Healthcare successfully completed its Initial Public Offering (IPO) and listed on NSE and BSE, marking a significant milestone in its journey.

Business Segments and Revenue Mix

• Contrast Media Intermediates: Blue Jet Healthcare is a leading global manufacturer of key intermediates crucial for the production of X-ray and MRI contrast agents, catering to innovator and generic pharmaceutical companies worldwide.

• High-Intensity Sweeteners: The company produces saccharin and its salts, along with acesulfame potassium, which are widely used as sugar substitutes in the food, beverage, and pharmaceutical industries.

• Pharmaceutical Intermediates & APIs: Engaged in the development and manufacturing of complex pharmaceutical intermediates for various therapeutic applications, including niche APIs and controlled substances, leveraging its expertise in multi-step synthesis.

Key Personnel

Akshay B. Goenka: Managing Director. With over two decades of experience, he has been instrumental in the company's strategic growth, global expansion, and operational excellence in specialty chemicals and pharmaceutical ingredients.

Subsidiaries and Associate Companies

No major subsidiaries reported.

Corporate Actions

2023: Initial Public Offering (IPO) on NSE and BSE.

References

1. Annual Report FY2023-24 2. Exchange Filings (NSE/BSE) 3. IPO Red Herring Prospectus (RHP)